Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
Recap by typeshit. Post by Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM on X.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
He says this average comes from his own clinical experience, adding that some strong responders drop more than 10 kg. A personal observation, not trial data.
Brown says diet and exercise still matter, but argues that shaming people for treating obesity with medication has never made anyone healthier.
A short share on growing GLP-1 use in the US, with no figures or sources attached. Thin on detail beyond the headline itself.
Loading…